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Abstract
Background: The increase in bacterial resistance phenotype cases is a global health problem. New strategies must
be explored by the scientific community in order to create new treatment alternatives. Animal venoms are a good
source for antimicrobial peptides (AMPs), which are excellent candidates for new antimicrobial drug development.
Cathelicidin-related antimicrobial peptides (CRAMPs) from snake venoms have been studied as a model for the
design of new antimicrobial pharmaceuticals against bacterial infections.
Results: In this study we present an 11 amino acid-long peptide, named pseudonajide, which is derived from a
Pseudonaja textilis venom peptide and has antimicrobial and antibiofilm activity against Staphylococcus epidermidis.
Pseudonajide was selected based on the sequence alignments of various snake venom peptides that displayed
activity against bacteria. Antibiofilm activity assays with pseudonajide concentrations ranging from 3.12 to 100 μM
showed that the lowest concentration to inhibit biofilm formation was 25 μM. Microscopy analysis demonstrated
that pseudonajide interacts with the bacterial cell envelope, disrupting the cell walls and membranes, leading to
morphological defects in prokaryotes.
Conclusions: Our results suggest that pseudonajide’s positives charges interact with negatively charged cell wall
components of S. epidermidis, leading to cell damage and inhibiting biofilm formation.
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Background
Several animals in different phyla in the animal kingdom
have developed the ability to produce venoms, including
annelids (e.g. bearded fireworm), arthropods (e.g. bees,
scorpions, and spiders), cnidarians (e.g. sea anemones),
echinoderms (e.g. sea urchins), mollusks (e.g. cone snails)
and vertebrates (e.g. snakes and mammals) [1, 2]. Animal
venoms are complex mixtures of inorganic salts, small or-
ganic molecules, high-molecular-weight proteins including
enzymes, and peptides, used for both protection and preda-
tion [2, 3]. Because they are both potent and specific in
their interactions with the cell wall and membrane compo-
nents of different cells, venom constituents are attractive
candidates for the development of novel therapeutics and
pesticides [4], although they remain largely unexplored.
The rich blend of molecules found in venoms contains
many antimicrobial peptides (AMPs) [1], and AMP se-
quences are available in various databases (such as http://
aps.unmc.edu/AP) [3]. AMPs have complex and wide-
ranging mechanisms of action. They can directly target bac-
terial membranes, damaging cell integrity and consequently
causing osmotic imbalance. They can also disrupt macro-
molecular synthesis, interfering in cell wall biosynthesis [5].
Due to this complexity and the widescale of their target in-
teractions, resistance to such molecules seems to arise less
commonly than with conventional antibiotics [6].
Cathelicidin-related antimicrobial peptides (CRAMPs)
from snake venoms (specially from Elapidae and Viperidae
families) have been studied as models for the design of new
antimicrobial pharmaceuticals against bacterial infections,
facilitated by complete genome sequences available [7].
These bioactive molecules are structurally characterized by
an N-terminal segment with a gene-encoded signal peptide
and a cathelin domain derived from the cathepsin L-
inhibitor (pro-peptide), followed by a C-terminal antimicro-
bial domain with diverse structures (mature peptide) [8].
Venom cDNA libraries from Naja atra, Bothrops atrox,
Crotalus durissus terrificus, Pseudonaja textilis, Ophiopha-
gus hannah, and Bungarus fasciatus snake species have re-
vealed different types of cathelicidins (NA-CATH,
batroxicidin, crotalicidin, Pt_CRAMP1, OH-CATH, OH-
CATH30, cathelicicin-BF) with remarkable antimicrobial
activity against Gram-positive and -negative bacteria, as
well as fungi [1, 9, 10].
About 75% of human microbial infections are promoted
by biofilm formation, which is increasingly recognized by
the public health community as an important source of
pathogens, especially in medical device-associated and
persistent infections [11]. Biofilms are well-organized mi-
crobial associations normally attached to abiotic or biotic
surfaces. Their structure is characterized by matrix accu-
mulation, and the formation process consists of several
stages (cell adherence, microcolonies formation, biofilm
maturation and dispersion) [12, 13]. There are several
advantages to this form [14]: a biofilm community is diffi-
cult to treat due to the physical barrier against antibiotics
and immune system factors [15]; and the structure is re-
lated to much higher antimicrobial resistance [16]. In
most cases, the first treatment option for biofilm on med-
ical devices is removal of the devices themselves, leading
to increases in both patient suffering and health system fi-
nancial expenditures [17].
Staphylococcus epidermidis is a commensal micro-
organism widely present on human skin [18], making
this species one of the main causes of infections related
to biofilm formation in medical devices [19, 20]. Indeed,
biofilm formation is the most prominent virulence factor
during the pathogenesis of S. epidermidis [21]. Com-
mensal skin flora or hospital bacteria can adhere to a
foreign body, replicate, and form a biofilm, which can
then for instance invade peri-implant tissue, causing ser-
ious infection [17, 22]. S. epidermidis infections on cen-
tral venous catheters occur annually in approximately
80,000 cases in the United States, leading to several
blood infection cases [23, 24]. Furthermore, S. epidermi-
dis is related to 17–39% of infections in prosthetic valve
endocarditis [25]. Due to this prevalence, and the global
increase in bacterial resistance, the search for new mole-
cules to treat bacterial infection is extremely urgent [26].
Here, we present pseudonajide, a synthetic peptide
made up of 11 amino acids and derived from Pseudonaja
textilis snake venom. The peptide possesses antimicrobial
and antibiofilm activity against S. epidermidis, and our re-
sults suggest that it acts on this bacteria’s cell wall and
membrane components quite quickly and at low doses.
Results
Snake venom antimicrobial peptides present highly
conserved motifs
A total of 170 antimicrobial peptide sequences from ant, bee,
centipede, cone snails, scorpion, snake, spider or wasp venoms
were analyzed. Sequence alignments within each taxonomic
groupwereperformedusingClustalX (Fig. 1 andAdditional files 1,
2, 3, 4, 5, 6 and 7). The alignment of snake sequences (Naja atra
- Cathelicidin NA-CATH; Bothrops atrox - Batroxicidin; Crotalus
durissus terrificus - Crotalicidin; Pseudonaja textilis - Cathelicidin
Pt_CRAMP1; Ophiophagus hannah - Cathelicidin OH-CATH;
Ophiophagus hannah - Cathelicidin OH-CATH30, and; Bun-
garus fasciatus - Cathelicicin-BF) revealed a greater number of
conserved motifs among snake peptides than that found in other
groups. Subsequently, 17 conserved amino acid sequences and
their close variants (Fig. 1) were selected as derived peptides for
antibiofilm and antimicrobial activity evaluations.
Peptides 1, 2, and 3 have antibiofilm activity in S.
epidermidis
The first aim of this work was to perform a screening
for antibiofilm activity in 17 synthetic small peptides
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derived from snake venom sequences. For that, we chose
two different species of bacteria, one Gram-negative
(Pseudomonas aeruginosa PAO1), and one Gram-
positive (S. epidermidis ATCCC 35984). The selection
took into account their biofilm production capabilities,
and their recognized value as good models for the study
Fig. 1 Peptide alignment and selection of snake venom derived peptides. (Top) Chart demonstrating the sequence alignment of seven peptides
derived from snake venom. (Bottom) After analysis with Clustal X software [27], 17 sequences of 7, 8 or 11 amino acids and different charges and
hydrophobicity were selected for antibiofilm and antimicrobial testing. The figure shows each snake venom derived peptide with respective
molecular weight (MW), isoelectric point (Pi), purity, and originating snake species
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of biofilm formation and structure [12, 28]. For screen-
ing, a crystal violet stain protocol was used in the absence
or presence of peptides at different concentrations. No ef-
fects were detected on biofilm formation by P. aerugi-
nosa (Additional file 8). On the other hand, peptides
1, 2, and 3 demonstrated strong activity against S.
epidermidis biofilm. After 24 h of exposure to differ-
ent concentrations, there was a considerable reduction
in biofilm mass (Fig. 2a). At a concentration of
100 μM, the biofilm mass was reduced by 77, 95, and
78% for peptides 1, 2, and 3, respectively (Fig. 2a).
Peptide 2 demonstrated greater antibiofilm activity
than peptides 1 and 3. The considerable reduction of
63% in biofilm formation in the presence of 25 μM of
peptide 2 led us to select that particular molecule at that
specific concentration for the following experiments. We
named the peptide “pseudonajide” after the name of the
snake it was derived from, Pseudonaja textilis. In order
to test its biofilm eradication activity, we pre-cultured S.
epidermidis cells for 24 h, adding pseudonajide to pre-
formed biofilm and incubating for another 24 h. The
final quantification of biofilm mass showed a reduction
of about 30% in the presence of the molecule (Fig. 2b).
Pseudonajide has antimicrobial activity against S.
epidermidis
We decided to test the antimicrobial activity over a
shorter period of time, because no difference had been ob-
served after 24 h. Growth and colony-forming unit (CFU)
tests were performed. Cells were incubated in the same
conditions as for the antibiofilm tests, with or without
25 μM pseudonajide. After 1, 2, 4, and 24 h incubation, we
measured the optical density at 600 nm (OD600) and
assessed the CFU counts. Figure 3 shows clearly that the
molecule caused a huge decrease in bacterial growth as
compared to the control. Accordingly, the number of vi-
able cells determined by CFU counts decreased after 1, 2,
or 4 h of incubation with pseudonajide.
Pseudonajide binds to the cell wall and membrane,
causing permeabilization
To better understand pseudonajide’s binding site, we
synthesized peptides tagged with fluorescein isothiocyan-
ate (FITC) for use in confocal microscopy experiments.
Cells were incubated with 25 μM FITC-tagged pseudo-
najide for 1, 4, or 24 h. After incubation, confocal micros-
copy showed that the molecule was located around or
inside the bacterial cell, but not in the biofilm matrix
(Fig. 4). Another important finding was the reduction in
the number of fluorescent cells over time, with decreased
peptide-tagged cell counts after 4 h and 24 h incubation.
To confirm that the interaction occurs between pseudo-
najide and S. epidermidis cell wall and membrane, we did
LIVE/DEAD experiments. It is demonstrated in the
literature that propidium ions can enter cells with high
membrane potential [30]. Cells were cultured for 4 h with
or without 25 μM pseudonajide. Confocal microscopy
image analysis demonstrated an increase in cell death
when in the presence of pseudonajide. Moreover, statis-
tical analysis shows that there was a significant decrease in
the number of impermeable cells (green) when the peptide
is present (Fig. 5). These data suggest that pseudonajide is
interfering with cell wall and membrane integrity.
Pseudonajide damages S. epidermidis cell wall and
membrane
To check for morphological changes in S. epidermidis cells
after exposure to the peptide, microscopy experiments were
then performed after 1, 4, and 24 h incubation with or with-
out 25 μM pseudonajide. We chose to approach this in two
distinct ways, using both scanning electron microscopy
(SEM) and transmission electron microscopy (TEM). The
SEM experiments were performed by culturing the cells in
the same conditions as before, with plastic slides added to
the culture well for cell adherence. Our most notable result
was that after 4 and 24 h incubation, cell adhesion was much
weaker when cultured with the peptide, although no differ-
ence was observed after just 1 h (Fig. 6). Another important
characteristic we noted was that several cells exposed to this
molecule had a shrunken morphology and were smaller than
non-exposed cells (Fig. 6, white arrows). Again, this morph-
ology was only noted after 4 h or 24 h incubation. A final
point that must be highlighted is that some extravasated
material was present surrounding the shrunken cells, as
was apparent in the SEM images (Fig. 6, white arrows).
None of these phenomena were observed in untreated
cultures. After the SEM experiments and analysis, two
questions remained unanswered: how does pseudonajide
causes cells to shrink? Is there any damage to the cell wall
or to the membrane? To address these questions, we per-
formed TEM. This imaging method allows for the analysis of
cell component ultrastructures and thus the analysis of cell wall
and membrane integrity. Analysis of the resulting images dem-
onstrated disrupted cells after pseudonajide exposure (Fig. 7,
dark arrows). Specifically, after 4 and 24h of peptide exposure,
the cell wall is not intact, and the cell sizes are completely differ-
ent than those of the control. Moreover, cytoplasmic material
looks condensed in peptide-exposed cells. (Fig. 7).
Pseudonajide increases the expression of genes coding
for teichoic acid synthesis
The results obtained from microscopy analysis led us to
hypothesize that pseudonajide acts on cell walls and membranes.
Indeed, cationic peptides are known to be able to interact with
the cell wall of Gram-positive bacteria [31] and to influence
membrane fluidity when engaging with the phospholipid bilayer
[32]. One of the first molecules that is supposed to interact with
cationic peptides is teichoic acid, a negatively charged molecule
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Fig. 2 (See legend on next page.)
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present in Gram-positive cell walls [33]. To investigate this, real-
time quantitative PCR tests were done, with S. epidermidis cul-
tured in the same conditions as the previous experiments.
Upon testing 4 h incubation with serially diluted doses
of pseudonajide (3 μM to 100 μM), the concentration of
6.25 μM, sufficient to inhibit 50% of bacterial growth
(Fig. 8), was selected for gene expression studies. Three
genes involved in teichoic acid biosynthesis (UgtP, LtaA
and LtaS) were tested and showed increased expression
levels in the presence of sub-lethal concentration of pseu-
donajide (Fig. 8b). These results led us to hypothesize that
pseudonajide interacts with teichoic acid in the S.
Fig. 3 Antimicrobial activity of pseudonajide (peptide 2). Staphylococcus epidermidis was cultured in the same conditions as the biofilm tests, but
with a different pseudonajide concentration (25 μM). a Optical density measurements at 600 nm (OD600) show a reduction in bacterial growth in
the presence of 25 μM pseudonajide (peptide 2) after 1, 2, and 4 h. b Colony-forming unit (CFU) testing confirmed the reduction in cell viability
as compared to the control. All the tests were performed with at least 3 different biological replicates, each having at least 3 technical replicates.
Error bars are shown, and statistical analysis was performed applying Student’s t-test, where: *, p < 0.05; **, p < 0.005; NS, non-significant
(See figure on previous page.)
Fig. 2 Antibiofilm and biofilm eradication activity. (A) Antibiofilm formation (left graphs) and bacterial growth (right graphs) after 24 h of
exposure to different concentrations of peptide 1, pseudonajide (peptide 2), or peptide 3. S. epidermidis ATCC 35984 cell suspension was
incubated alone or in the presence of decreasing concentrations of peptides. An adapted crystal violet protocol was used for biomass
measurement at optical density of 570 nm (OD570) [29], and growth analysis was done at an optical density of 600 nm (OD600). Culture medium
with 2% dimethyl sulfoxide (DMSO), and culture medium alone were used as growth control, while rifampicin was the antibiofilm positive
control. OD600 was measured at time zero and at 24 h for growth normalization. (B) The biofilm eradication activity of pseudonajide (peptide 2),
pseudonajide (bottom graph) was measured by adding 25 μM of pseudonajide in pre-formed biofilm and incubating for further 24 h. All the tests
were performed with at least 3 different biological replicates each including at least 3 technical replicates. Error bars are shown, and statistical
analysis was performed using Student’s t-test, where: *, p < 0.05; **, p < 0.01; ***, p < 0.001
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epidermidis cell wall, causing a strong interaction with this
structure, and leading to cell permeability. The same ex-
tracted RNA sample was used for expression analysis of
nine biofilm-related genes: atlE, agrC, aap, embP, icaA,
leuA, saeR, saeS, and sarA. No significant differences in
expression were observed between control and peptide-
treated conditions for these nine genes (Fig. 8c).
Pseudonajide interacts with lipoteichoic acid (LTA)
in vitro
To probe the interaction between pseudonajide and LTA,
we performed binding experiments by fluorescence
polarization (FP) using FITC-tagged pseudonajide. Peptide
concentration was set constant to 5 μM while LTA mono-
mer concentration varied from 2.5 μM to 5mM. Titration
series was set in triplicates. FITC-pseudonajide FP increased
with LTA concentration, an indication of binding between
the two molecules (Fig. 9). The LTA concentration range
used allowed us to observe an almost complete titration
curve. Mid titration occured at around 50 μM LTA. The sig-
moid rise is sharper than expected for a 1:1 binding model,
indicating cooperative binding of more than one molecule of
LTA per peptide. Albeit observed in vitro, these results
strongly support the conclusion derived from microscopy
Fig. 4 Pseudonajide is located on the cell envelope and inside the bacterial cell. a Confocal microscopy images of Staphylococcus epidermidis
incubated for 1, 4, and 24 h with 25 μM pseudonajide tagged with fluorescein isothiocyanate (FITC). Scale, 10 μm. Cells were washed once with
saline solution, and 3 μL cell suspension were added to each glass slide. b Graph demonstrating the percentage of cells that were fluorescent at
each time point. Shown are 5 random fields, with approximately 1000 cells counted for each time point. Calculated by dividing the number of
fluorescent cells by the total number of cells in the field. Images were analyzed using Fiji software
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and RT-qPCR that pseudonajide interacts with the cell walls
and membranes of Gram-positive bacteria by binding to
lipoteichoic and teichoic acids. This would also explain why
the peptide is not active against Gram-negative bacteria like
Pseudomonas aeruginosa.
Pseudonajide is not cytotoxic to human cells
One of the main challenges in the development of anti-
microbial peptides as therapeutics is their potential tox-
icity to human cells [35, 36]. We therefore performed
toxicity tests using seven human cell lines: HuH7 (hepa-
tocellular carcinoma); Caco-2 (colorectal adenocarcin-
oma); MDA-MB231 (breast adenocarcinoma); HCT116
(colorectal carcinoma); PC3 (prostatic adenocarcinoma);
NCL-H727 (lung carcinoma); and MCF7 (breast cancer).
After 24 h incubation with pseudonajide at 25 μM, there
was no decrease in live cell counts compared to the con-
trol conditions (Fig. 10), indicating that pseudonajide is
not cytotoxic to human cells.
Discussion
Antimicrobial peptides are promising molecules in the
fight against bacterial resistance [37]. Since AMPs can
interact with a large variety of cell targets, they have an
advantage in the fight against the production of bacterial
resistance phenotypes [38]. Currently only three natural
cathelicidins have had their antibiofilm activity reported
(NA-CATH, CATHPb1, and SA-CATH) [7, 39–41].
Synthetic derivatives from these natural cathelicidins
were tested and showed improved anti-biofilm activity in
comparison with natural NA-CATH peptide [41].
Our first goal in the present work was to screen for new
molecules with antibiofilm activity in two biofilm-forming
models, S. epidermidis and P. aeruginosa. We have found that
most of the 17 short snake-venom derived peptides tested
here had no effect against P. aeruginosa (Additional file 8) or
S. epidermidis (Additional file 9). We go on to demonstrate
that an 11-amino acid peptide derived from P. textilis snake
venom (peptide 2), herein named pseudonajide possesses
Fig. 5 LIVE/DEAD experiments in the presence of pseudonajide. a Confocal microscopy images showing cells (left) unexposed and (right)
exposed to the molecule. After incubation, cells were treated with LIVE/DEAD BacLight reagent (Thermo Fisher). b Graph of the percentages of
DEAD (red) and LIVE (green) cells. At least 1000 cells were counted in more than 10 randomly chosen fields per condition, and the experiments
were performed in triplicate for each time point. Bars represent the standard deviation. Statistical analysis comparing results to the respective
control conditions (Student’s t-test): *, p < 0.05
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antimicrobial activity against S. epidermidis. When we investi-
gated the mechanism of action of pseudonajide, we found that
it acts directly on the bacterial cell, and not on the biofilm
matrix. This led us to investigate its antimicrobial activity, the
molecule’s cellular binding site, as well as the bacterial mole-
cules which might interact with this newly identified peptide.
To analyze the effects of pseudonajide on S. epidermi-
dis cells, we performed growth curve and CFU experi-
ments using a concentration of the peptide of 25 μM.
We began by investigating the peptide’s effects in the early
stages of interaction. In fact, it is possible to detect a great
difference in the CFU counts after just 1, 2, and 4 h incuba-
tion, which is characteristic of a fast-acting antibiotic. More-
over, biofilm eradication activity was detected (Fig. 2d), with
around 30% lower biofilm mass as compared to the control
conditions, possibly due to the ability of pseudonajide to kill
the biofilm-forming bacteria. This shows that the peptide
has a dual action, both antimicrobial and against biofilm for-
mation. To discover the binding sites of pseudonajide, we
produced an FITC-tagged molecule. After 1, 2, and 24 h
interaction with bacterial cells, confocal microscopy demon-
strated that pseudonajide interacts with the S. epidermidis
cell envelope (Fig. 4). We can therefore suggest that the first
point of interaction for pseudonajide is the cell envelope, and
not the biofilm matrix.
Based on their activities, AMPs can be divided into
two main groups: they can act on the cell wall and dis-
rupt the membrane, causing cell permeability; or they
can have intracellular targets [42, 43]. Even though cat-
ionic peptides can have different amino acid sequences,
they still have similar characteristics which permit inter-
action with bacterial cell membranes. As described in
the literature, most of the residues in AMPs are posi-
tively charged and some are hydrophobic, ensuring the
AMPs amphipathic character [31, 44]. In this work,
structural analysis demonstrated that more than 50% of
the amino acids which make up the peptide pseudona-
jide are positively charged (KRFKKFFMKLK). The pres-
ence of methionine (M) or suppression of lysine (K) at
position 8 seems to increase the antimicrobial/antibio-
film activity of pseudonajide. Methionine residue was
not seen in peptides 1 (KRFKKFFKKVK) or 3 (KRFKKF
FKKLK).The antimicrobial peptide sequence from which
pseudonajide was identified and synthesized was origin-
ally reported by Falcão’s group [10], and belongs to the
vipericidins, a family of cathelicidin-related peptides de-
rived from the venom glands of South American pit vi-
pers. They described these vipericidins as having
antimicrobial activities against different bacteria, includ-
ing S. aureus and P. aeruginosa strains. We have
Fig. 6 Scanning electron microscopy images of Staphylococcus epidermidis in the presence or absence of pseudonajide. Bacterial cells were
cultured with or without 25 μM pseudonajide (peptide 2) for 1, 4, and 24 h. Plastic slides were placed inside the culture well plates and used to
analyze biofilm and cell morphology. White arrows indicate the cells with different morphologies at 4 and 24 h in the presence of pseudonajide.
Images are shown at 500 and 10,000x magnification, and were obtained using a JEOL JSM-7100F scanning electron microscope
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evidence that pseudonajide is acting on the cell wall and
membrane of S. epidermidis. It is reported in the litera-
ture that AMPs bind preferentially to the cationic bac-
terial membrane instead of the zwitterionic membrane
in mammalian cells [44]. Moreover, pseudonajide con-
tains 36% hydrophobic amino acids, a characteristic
which may explain its interactions with the bacterial cell
membrane. Insertion of the peptide into the hydropho-
bic portion of the membrane seems to cause osmotic
imbalance in the cell, which could lead to the shrunken
cell morphology observed in the SEM (Fig. 6) and TEM
(Fig. 7) analyses. It is important to note that in TEM, the
defective cells have external material surrounding them.
We hypothesize that this consists of extravasated DNA
and disorganized peptidoglycan, but more tests are ne-
cessary to prove it. We also surmise that the smaller
cells that can be observed are the same as those seen on
FITC-tagged peptides with confocal microscopy. The
green fluorescent cell sizes were all smaller than those of
the non-fluorescent cells. In summary, pseudonajide acts
on the cell envelope, likely inducing osmotic stress that
leads to a reduction in cell size (Fig. 5).
The cell wall in Gram-positive bacteria is a complex
network of molecules in a structure composed mainly of
peptidoglycan and teichoic acids. Teichoic acids are
negatively charged poly-glycerophosphate chains that
can be linked to peptidoglycan or anchored to the cyto-
plasmic membrane [45, 46]. Moreover, D-alanylation of
Fig. 7 Transmission electron microscopy images of Staphylococcus epidermidis in the presence or absence of pseudonajide. S. epidermidis cells
were cultured with or without 25 μM of the peptide and imaged at three different time points. Cells were detached from the well plate using
disposable tips, and all content was treated following the TEM protocol (Materials and Methods). Dark arrows indicate cell wall defects and
membrane disruption in the presence of pseudonajide. Scale bars, 200 nm
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lipoteichoic acid is said to promote protection against
cationic AMPs in Gram-positive bacteria [47]. In order
to test this, we assessed the expression levels of genes
coding for LTA assembly molecules, namely glycosyl-
transferase YgfP (UgtP), flippase LtaA, and lipoteichoic
acid synthase LtaS [48]. In S. aureus, lipoteichoic acid
synthesis starts with YgfP, encoded by the ugtP gene.
This protein synthesizes the glycolipid anchor Glc2-
DAG from UDP-Glc and diacylglycerol (DAG). Glc2-
DAG is translocated to the outside of the membrane by
Fig. 8 Gene expression analysis. Graphs of gene expression analysis for three genes coding for the lipoteichoic acid assembly cascade. a Bacterial
growth after 4 h exposure to different concentrations of pseudonajide (peptide 2). Culture medium with 2% DMSO was used as a control, and
rifampicin was the antibiofilm positive control. OD600 was measured at time zero and at 24 h for growth normalization. For gene expression
analysis, cDNA was obtained through reverse transcriptase reactions on mRNA extracted from Staphylococcus epidermidis cultured in the presence
(peptide) or absence (control) of 6.25 μM pseudonajide. b Expression levels of genes ugtP, ltaA, and ltaS under the same testing conditions. c
Expression levels of biofilm-related genes under these same conditions. The 2-ΔΔct method was used to normalize expression levels to 16S rRNA
[34]. All tests were performed in at least 3 different biological replicates each having at least 3 technical replicates. Error bars are shown, and
statistical analysis was performed using Student’s t-test, where: *, p < 0.05
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LtaA [48, 49], and elongation of the LTA chain is then
promoted by LtaS [48, 50]. Based on the literature and
due to the physicochemical characteristics of teichoic
acids, we speculated that pseudonajide must act on
teichoic acids on S. epidermidis cell wall. We detected
increased expression of all three tested genes when
the cells were cultured in the presence of pseudona-
jide (Fig. 8b). Our fluorescence polarization experi-
ments indicated an interaction between pseudonajide
and lipoteichoid acids, which probably caused cell
Fig. 9 Interaction between pseudonajide and LTA. The Klotz plot of the fluorescence polarization vs LTA concentration indicates the interaction
between FITC-pseudonajide and LTA. Measurements were recorded in water for a FITC-pseudonajide constant concentration of 5 μM and LTA
monomer concentrations corresponding to 0.5, 1, 5, 10, 50, 100, 500 and 1000 M equivalents. Titration series were set in triplicates. Data points
arrange along with a sigmoid. Fitting according to a 1:1 model discloses a mid-titration corresponding to a Kd in the range of 47-51 μM. The
sharper and steeper rise of the sigmoid is evocative of a cooperative binding process
Fig. 10 Evaluation of pseudonajide cytotoxicity. Graph demonstrating the percentage of living cells after 24 h exposure to 25 μM of each peptide.
For the tests, seven different human cell lines were used. For comparison, the number of living cells in the DMSO control was considered as
100%, and the three cytotoxic drugs roscovitine, doxorubicin, and taxol were used as positive controls. All tests were performed at the ImPACcell
automatized platform of cytotoxicity evaluation (Université de Rennes 1)
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wall disorganization in S. epidermidis (Fig. 11). The
induced increase in gene expression may well be a
compensatory mechanism to protect against the pres-
ence of the peptide, preserving cell viability. It was
already described that exposure to daptomycin, a lipo-
peptide antibiotic, causes increased expression of lipo-
teichoic acid-related genes, and that is associated with
cell wall stress [47, 51].
It was previously suggested that cationic antimicrobial
peptides kill bacterial cells. They first interact with the
membrane through electrostatic interactions [52], con-
tacts which result in membrane disruption and cell
death. Other peptides can cross the bacterial lipid bilayer
without causing any damage to the cell membrane, but
still inhibit intracellular functions, so they also eventually
lead to bacterial death. Pseudonajide consists of an
amino acid sequence (KRFKKFFMKLK) that is part of a
peptide isolated from P. textilis venom. Among the
peptides we tested, pseudonajide has the best anti bio-
film formation activity, at a sub-MIC concentration of
just 6.25 uM (Fig. 2b), and the best eradication of estab-
lished biofilm activity in the group (Fig. 2d). Several
AMPs have been described as also having antimicrobial
activity against Gram-negative bacteria. In the present
work, we did not observe any antibiofilm or antimicro-
bial activity against P. aeruginosa (Additional file 8). Fur-
ther studies are needed to assess possible mechanisms
that explain this overall lack of activity against P. aerugi-
nosa. Short peptides such as the ones we tested might
suffer degradation by P. aeruginosa proteases [53, 54],
since small peptides are typically more susceptible to
these enzymes. A P. aeruginosa metalloprotease is prob-
ably involved in degradation of an antimicrobial peptide
named GL13K [55]. In Proteus mirabilis, the ZapA-zinc
metalloprotease is able to cleave LL-37 as well as β-
defensin 1 [56]. The inhibition of LL-37 bactericidal
Fig. 11 Proposed mechanism of action for pseudonajide (peptide 2). a Schematic of the proposed mechanism of action of pseudonajide in the
cell walls and membranes of Gram-positive bacteria. The cationic peptide is shown interacting with negative charges from the cell wall
components and with the hydrophobic portions of bacterial membranes. Such interactions lead to: (b) cell envelope binding, shown in a
confocal microscopy image; (c) defective morphology, observed by scanning electron microscopy; and (d) cell wall and membrane fractures,
observed by transmission electron microscopy
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activity by alginate and exopolysaccharides is another ex-
ample of antimicrobial peptide defense reported in P.
aeruginosa. The inhibition occurs through LL-37 seques-
tration, which diminishes AMP concentrations at the
target site [57].
We have observed pseudonajide’s dual activity, as it is
both antimicrobial and also inhibiting S. epidermidis bio-
film formation. Even though we did not see any alter-
ation in the expression of biofilm-related genes when
the peptide was present, we did observe biofilm eradica-
tion with reduction in mass (Fig. 2b). This decrease can
be explained by several elements. One is the relationship
between the cell wall teichoic and lipoteichoic acids and
the processes of adhesion and biofilm formation [58]. In
S. epidermidis, cell wall teichoic acids seem to induce
adhesion-immobilized fibronectin [59]. Moreover, these
types of molecules have been detected in the biofilm
matrix of S. epidermidis [60]. If pseudonajide mainly acts
on teichoic and lipoteichoic acids, the reduction in adhe-
sion could be one of the causes of both biofilm reduc-
tion and outright eradication. It is also important to
emphasize the characteristics of cationic antibiofilm pep-
tides, described by Von Borowski et al. [61]. They
showed that lysine (K) and phenylalanine (F) are the
most frequently found amino acids in antibiofilm pep-
tides, and this is clearly also the case for pseudonajide
(KRFKKFFMKLK).
Conclusions
We have showcased here the promising activity of a syn-
thetic peptide derived from P. textilis venom. Its dual ac-
tion against S. epidermidis cells and biofilms make
pseudonajide a very promising molecule for new drug
development, and this is reinforced by the fact that it
has a short 11 amino acid sequence. Shorter sequences
are advantageous both for industry and antimicrobial
peptide researchers, as they are easier to synthesize and
cost less. Importantly, this facilitates future research into
their structures and into ways to improve their
efficiency.
Methods
Peptides alignment and synthesis
A list of 170 antimicrobial peptides from animal venoms,
reviewed previously by our research group [1], was used
to perform amino acid sequence alignments in Clustal X,
to investigate the presence of conserved motifs and to gain
structural and functional insights about those AMP se-
quences. Alignments were analyzed and the selected se-
quences were synthesized by GenOne Biotechnologies®,
with respective HPLC and mass spectrum analysis (Add-
itional files 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,
23, 24, 25 and 26). The synthetic peptides were then solu-
bilized in 0.5% DMSO and used for further testing.
Bacterial strains and culture conditions
S. epidermidis ATCC 35984 and Pseudomonas aerugi-
nosa PAO1 were used to test the antimicrobial and anti-
biofilm activities of the peptides. Both bacteria were
grown in blood agar plates and cultured overnight at
37 °C. Cell suspensions were prepared in a solution of
0.9% NaCl and adjusted to OD600 for a final concentra-
tion of ~ 10
8 cells/ml. For microscopy analysis, pre-
inoculum was made in tryptic soy broth (TSB, Merck),
and adjusted to OD600 for the same concentration of
cells for all tests.
Tests of antimicrobial and antibiofilm activity
Serial dilution of peptides was performed in 96-well
plates, going from 100 to 3.12 μM. Cell suspensions and
TSB were added to the plates and a control was made
with dimethyl sulfoxide (DMSO). Antibiofilm formation
tests were performed with an adapted protocol [62], in
which it is described that 24 h of incubation is sufficient
to determinate antibiofilm activity. The OD600 was mea-
sured, then biofilm content accessed using the crystal
violet protocol [29]. Biofilm eradication test was per-
formed supplementing 24 h pre-formed biofilm with a
new culture broth, containing or not 25 μM of peptide.
The plates were incubated for further 24 h followed by
crystal violet protocol. The antimicrobial activity of
pseudonajide was analyzed using a concentration of
25 μM after 1, 2, 4, and 24 h incubation. After measuring
the optical density, the supernatant was collected and di-
luted. A volume of 100 μl was plated in Luria broth agar
plates. CFUs were counted after 24 h incubation. All ex-
periments were performed at least three different times,
each with three technical replicates.
Scanning electron microscopy
S. epidermidis was cultured in the same conditions as
described previously, in the presence or absence of
25 μM pseudonajide. However, for this analysis, a plastic
slide was placed inside each well, and these plates were
incubated for 1, 4, and 24 h. After incubation, the plastic
slides were washed three times with 0.9% NaCl solution
and fixed overnight in fixation buffer (2.5% glutaralde-
hyde, 2% paraformaldehyde, 0.1M sodium cacodylate) at
4 °C. The adhered cells were then dehydrated with in-
creasing concentrations of ethanol solutions. The images
were obtained using a JSM-7100F scanning electron
microscope (JEOL).
Transmission electron microscopy
Bacterial cells were cultured in 24-well plates in the
presence or absence of 25 μM of pseudonajide. Cells
were incubated for 1, 4, and 24 h. All of the content in
the well was recovered, centrifuged at 12,000 g, then
washed with saline solution. Fixation was performed for
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18 h at 4 °C in buffer (0.2 M sodium cacodylate, 16%
paraformaldehyde, 25% glutaraldehyde, 75 mM lysine).
Samples were then washed 4 times with a solution con-
taining 0.1M sodium cacodylate and 0.2M sucrose.
After each resuspension, samples were incubated for 10
min in this solution. Contrast was done for 1 h with a so-
lution of 1% osmium tetroxide and 1.5% potassium ferro-
cyanure. Dehydration was induced by gradually
introducing a solution of ethanol, and infiltration with in-
creasing concentrations of LR white resin (Delta Micros-
copies) diluted in ethanol. Inclusion and polymerization
were performed over 24 h at 60 °C in capsules with LR
white resin in the absence of O2. Thin sections (80 nm)
were collected onto 200-mesh carbon grids and visualized
with a FEI Tecnai Sphera microscope operating at 200 kV
and equipped with a Gatan 4x4k UltraScan CCD camera.
Confocal microscopy
Bacterial cultures were done in the same conditions
as described above, but they were incubated with
pseudonajide tagged with FITC. After incubation, cells
were washed with saline solution, then 3 μL were
added to glass slides for confocal analysis. The images
were acquired using a Leica SP8 DMI 6000 CS con-
focal microscope, and ImageJ software was used for
image analysis.
Gene expression analysis
Quantitative real-time PCR (qRT-PCR) was performed
on RNA extracted from bacteria cultured during 4 h
with or without 6.25 μM of pseudonajide. Nucleic acids
were extracted using TRIzol reagent (Thermo Fisher)
following the manufacturer’s protocol. RNAse-free
DNAse I (NEB) was added to 2 μg RNA, then 1 μg RNA
was used for reverse transcriptase (RT) reactions with
M-MLV reverse transcriptase enzymes (Promega). RT
reactions were done using Random Primers (Promega).
For the qRT-PCR assay, 10 ng cDNA was used with
SYBR Green PCR Master Mix (Applied Biosystems) sup-
plemented with the respective primers [48]. The reac-
tions were performed in a StepOne Real-Time system
(Thermo Fisher). Expression levels of the 16S rRNA
gene were used for the relative gene expression
normalization analysis [34]. The primers used in this
work are listed in Table 1.
Toxicity test
Cytotoxicity tests were performed on the ImPACcell
robotic platform (BIOSIT, Université de Rennes 1).
This featured high-throughput multiparameter image
analysis, with both high-content screening and high-
content analysis. The platform is equipped with an
Olympus microscope and Compix SimplePCI soft-
ware; a Zeiss Axio Imager M1 microscope with a
Zeiss camera and AxioVision software; and imaging
systems including an ArrayScan VTI Cellomics reader
(Thermo Fisher), Hamilton STARlet and NIMBUS
workstations, and a Scienion spotter. Cells used in
the test were obtained from an already-existing col-
lection available at BIOSIT (https://biosit.univ-
rennes1.fr/impaccell-imagerie-pour-analyse-du-con-
tenu-cellulaire). For the tests, seven different cell lines
were used: human hepatocellular carcinoma (HuH7);
colorectal adenocarcinoma (Caco-2); breast adenocar-
cinoma (MDA-MB231); colorectal carcinoma
(HCT116); prostatic adenocarcinoma (PC3); lung car-
cinoma (NCL-H727); and breast cancer (MCF7). The
residual cell percentages reported correspond to viable
cells compared to the average viable cells in the
DMSO control. Viability of 100% represents no cyto-
toxicity or inhibition of cell growth, while under 25–
30% is considered cytotoxic and 0% represents acute
cytotoxicity.
Table 1 Primers used in this work
Gene Forward primer 5'-3' Reverse primer 5'-3' Amplicon
atlE TACCAGGGTTTGCAGGATTC GGCGCTAAATTCATTGGAAA 85 bp
aap AGGCCGTACCAACAGTGAAT ATGGGCAAACGTAGACAAGG 100 bp
agrC TCATCAATATCGCATTCATCG CCTAAACCGCGATTATCACC 136 bp
icaA TTATCAATGCCGCAGTTGTC CCGTTGGATATTGCCTCTGT 104 bp
leuA GATGATCTCGGAATGGCAGT TGAGGCATTTCCTGCTCTTT 108 bp
saeR GCTAACACTGTCAATGTCCACA AGGCCCCACACAGTTGTAAT 92 bp
saeS GGCGTCAATTTGTTGTGCTA AGGGCATAGGTATCGTTCCA 140 bp
sarA TTTGCTTCTGTGATACGGTTGT CGTAATGAACACGATGAAAGAACT 107 bp
ugtP (45) AAGCTGGTGTTCCTGCTTC ATGACCACTTGCGAATTTGG 216 bp
ltaA (45) GCCTTGGTTGTGCTTATTGC GGAAGAATAGGTACAAGTGC 184 bp
ltaS (45) ATGGTAAAGAGGTTACACC CCTTCAGTGAATAGGCTGAG 172 bp
qPCR16sRNA(45) AGGAGTCTGGACCGTGTCTC GCGTAGCCGACCTGAGAG 51 bp
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Fluorescence polarization
Fluorescence polarization measurements were con-
ducted on a CLARIOstar (BMG Labtech) spectropho-
tometer in a Greiner 364-well flat bottom black
microplate. Data were acquired at 23 °C in water using
the FITC fluorescence of FITC-pseudonajide and 35
flashes in standard mode. FITC-pseudonajide concentra-
tion was set to 5 μM and volume was adjusted to 20 μL
in all wells. S. aureus LTA was purchased from Sigma.
Titration series was set in triplicate using LTA monomer
concentrations ranging from 2.5 μM to 5mM. Data were
recorded within one hour, analyzed using Kaleidagraph
(Synergy Software) and fitted using a 1:1 model and the
following equation: Pobs = Pfree + [[(Pmax-Pfree)/2C0] *
[(Kd + L0 + C0)-((Kd + L0 + C0)
^2-4C0L0)
^0.5]] with P =
polarization, C0 = pseudonajide concentration, L0 = total
LTA concentration.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12866-020-01921-5.
Additional file 1. Alignment of ant peptide sequences using Clustal X
program.
Additional file 2. Alignment of bee peptide sequences using Clustal X
program.
Additional file 3. Alignment of centipede peptide sequences using
Clustal X program.
Additional file 4. Alignment of cone snail peptide sequences using
Clustal X program.
Additional file 5. Alignment of scorpion peptide sequences using
Clustal X program.
Additional file 6. Alignment of spider peptide sequences using Clustal
X program.
Additional file 7. Alignment of wasp peptide sequences using Clustal X
program.
Additional file 8 Antibiofilm formation testing of 16 short peptides in P.
aeruginosa. Graphs demonstrating biofilm mass quantification at OD570
by the crystal violet protocol (left) and growth at OD600 (right) in the
presence of different concentrations of 16 peptides. Tests were
performed over 24 h. Gentamicin was used as the antibiofilm and
antibiotic control, while TSB culture medium and TSB containing 2%
DMSO were used as biofilm formation and growth controls.
Additional file 9 Antibiofilm formation activity screening of 14 short
peptides in S. epidermidis. Graphs showing biofilm mass quantification at
an optical density of 570 nm (OD570) using the crystal violet protocol
(light gray), and growth at OD600 (dark gray), in the presence of different
concentrations of 14 peptides. TSB culture medium with 2% dimethyl
sulfoxide (DMSO) was used as a control for biofilm formation and
growth, and rifampicin was the antibiofilm and antibiotic positive control.
OD600 was measured at time zero and at 24 h for growth normalization.
Additional file 10. Peptide 1: A) HPLC analysis chromatogram. B) Mass
spectrum.
Additional file 11. Peptide 2: A) HPLC analysis chromatogram. B) Mass
spectrum.
Additional file 12. Peptide 3: A) HPLC analysis chromatogram. B) Mass
spectrum.
Additional file 13. Peptide 4: A) HPLC analysis chromatogram. B) Mass
spectrum.
Additional file 14. Peptide 5: A) HPLC analysis chromatogram. B) Mass
spectrum.
Additional file 15. Peptide 6: A) HPLC analysis chromatogram. B) Mass
spectrum.
Additional file 16. Peptide 7: A) HPLC analysis chromatogram. B) Mass
spectrum.
Additional file 17. Peptide 8: A) HPLC analysis chromatogram. B) Mass
spectrum.
Additional file 18. Peptide 9: A) HPLC analysis chromatogram. B) Mass
spectrum.
Additional file 19. Peptide 10: A) HPLC analysis chromatogram. B) Mass
spectrum.
Additional file 20. Peptide 11: A) HPLC analysis chromatogram. B) Mass
spectrum.
Additional file 21. Peptide 12: A) HPLC analysis chromatogram. B) Mass
spectrum.
Additional file 22. Peptide 13: A) HPLC analysis chromatogram. B) Mass
spectrum.
Additional file 23. Peptide 14: A) HPLC analysis chromatogram. B) Mass
spectrum.
Additional file 24. Peptide 15: A) HPLC analysis chromatogram. B) Mass
spectrum.
Additional file 25. Peptide 16: A) HPLC analysis chromatogram. B) Mass
spectrum.
Additional file 26. Peptide 17: A) HPLC analysis chromatogram. B) Mass
spectrum.
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